Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cash-rich Japanese Pharma Now In A Position To Snatch Up Compounds, But Many Face Decision-making Bottlenecks - BIO Japan

This article was originally published in PharmAsia News

Executive Summary

YOKOHAMA, Japan - The impact of the strong yen appreciation has been severe for Japanese companies, contributing to sales dips as foreign markets balked at the rising prices for Japanese products. But the strong yen can also be a positive for Japanese consumers, including Japan Pharma shopping around for early-stage biotech compounds
Advertisement

Related Content

Daiichi Sankyo Taps Japan Government Capital For New Seed Fund
Prism Finds Funding From Japanese Government VC To Launch New Trials
Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout
Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout
Advertisement
UsernamePublicRestriction

Register

SC076417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel